deferiprone has been researched along with Atherosclerotic Parkinsonism in 2 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 1 |
| Pham, AN | 1 |
| Waite, TD | 1 |
| Workman, DG | 1 |
| Tsatsanis, A | 1 |
| Lewis, FW | 1 |
| Boyle, JP | 1 |
| Mousadoust, M | 1 |
| Hettiarachchi, NT | 1 |
| Hunter, M | 1 |
| Peers, CS | 1 |
| Tétard, D | 1 |
| Duce, JA | 1 |
2 other studies available for deferiprone and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
Topics: Animals; Deferiprone; Disease Models, Animal; Dopamine; Iron; Iron Chelating Agents; Oxidative Stres | 2018 |
Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.
Topics: Cell Line; Crystallography, X-Ray; Deferiprone; Humans; Iron Chelating Agents; Models, Molecular; Ne | 2015 |